Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis

被引:222
|
作者
Ardizzone, Sandro [1 ]
Cassinotti, Andrea [1 ]
Duca, Piergiorgio [2 ]
Mazzali, Cristina [2 ]
Penati, Chiara [1 ]
Manes, Gianpiero [1 ]
Marmo, Riccardo [3 ]
Massari, Alessandro [1 ]
Molteni, Paola [1 ]
Maconi, Giovanni [1 ]
Porro, Gabriele Bianchi [1 ]
机构
[1] L Sacco Univ Hosp, Gastroenterol Unit, Dept Clin Sci, Milan, Italy
[2] L Sacco Univ Hosp, Sect Med Stat & Biometry, Milan, Italy
[3] Azienda Sanit Locale Salerno, Unita Operat Gastroenterol Polla, Salerno, Italy
关键词
Inflammatory Bowel Diseases; Endoscopy; Clinical Course; Mucosal Healing; INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; NATURAL-HISTORY; THERAPY; RELAPSE; PROCTOCOLITIS; PARAMETERS; COLECTOMY; GENDER; RISK;
D O I
10.1016/j.cgh.2010.12.028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. METHODS: Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel-Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0-1; Baron, 0), partial (group B: PT, 0-1; Baron, 1-3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. RESULTS: After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21-6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67-25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24-32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12-6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193-51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556-8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278-55.186; P = .0268). CONCLUSIONS: No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.
引用
收藏
页码:483 / U117
页数:10
相关论文
共 50 条
  • [41] Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
    Yokoyama, Kaoru
    Kobayashi, Kiyonori
    Mukae, Miyuki
    Sada, Miwa
    Koizumi, Wasaburo
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2013, 2013
  • [42] Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium
    Kochhar, Gursimran
    Parikh, Malav
    Chaudrey, Khadija
    Shmidt, Eugenia
    Luo, Michelle
    Barocas, Morris
    Boland, Brigid
    Singh, Siddharth
    Hudesman, David
    Swaminath, Arun
    Lukin, Dana
    Sands, Bruce
    Colombel, Jean-Frederic
    Sandborn, William
    Siegel, Corey
    Loftus, Edward, Jr.
    Kane, Sunanda
    Shen, Bo
    Dulai, Parambir
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S6 - S6
  • [43] Mucosal Healing in Patients with Ulcerative Colitis During a Course of Selective Leukocytapheresis Therapy: A Prospective Cohort Study
    Yamamoto, Takayuki
    Umegae, Satoru
    Matsumoto, Koichi
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (11) : 1905 - 1911
  • [44] SERUM CYTOKINES AND CHEMOKINES IN NEWLY DIAGNOSED ULCERATIVE COLITIS PATIENTS PREDICTING EFFECT ON TREATMENT AND DISEASE COURSE
    Roosenboom, Britt
    Smids, Carolijn
    Wahab, Peter
    Groenen, Marcel
    Nierkens, Stefan
    van Koolwijk, Elly
    Horjus, Carmen S.
    Horje, Talabur
    van Lochem, Ellen
    GASTROENTEROLOGY, 2018, 154 (06) : S1014 - S1015
  • [45] Serum IL-17A in Newly Diagnosed Treatment-Naive Patients with Ulcerative Colitis Reflects Clinical Disease Severity and Predicts the Course of Disease
    Ohman, Lena
    Dahlen, Rahil
    Isaksson, Stefan
    Sjoling, Asa
    Wick, Mary-Jo
    Sjovall, Henrik
    Van Oudenhove, Lukas
    Simren, Magnus
    Strid, Hans
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (11) : 2433 - 2439
  • [46] Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis
    Leong, R.
    Sands, B.
    Peyrin-Biroulet, L.
    Marano, C.
    Miao, Y.
    Izanec, J.
    Feagan, B.
    Rubin, D.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I102 - I103
  • [47] LONG-TERM OUTCOMES AFTER HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING: RESULTS FROM THE UNIFI STUDY IN ULCERATIVE COLITIS
    Sands, Bruce E.
    Leong, Rupert
    Peyrin-Biroulet, Laurent
    Marano, Colleen W.
    Miao, Ye
    Izanec, James L.
    Feagan, Brian G.
    Rubin, David T.
    GASTROENTEROLOGY, 2022, 162 (07) : S616 - S616
  • [48] COMPARING ORAL CORTICOSTEROIDS ≥30MG/DAY AMONG ADULT AND PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED ULCERATIVE COLITIS
    Hunter, Theresa
    Naegeli, April
    Larkin, Amy
    Komocsar, Wendy
    Schroeder, Krista
    Zhang, Xiang
    Stefani-Hunyady, Diana
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S45 - S45
  • [49] Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis
    Kim, Won Ho
    Yoon, Jin Young
    Jeon, Soung Min
    Hong, Sung Pil
    Kim, Tae Il
    Cheon, Jae Hee
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S49 - S50
  • [50] COMPARING ORAL CORTICOSTEROIDS ≥30MG/DAY AMONG ADULT AND PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED ULCERATIVE COLITIS
    Hunter, Theresa
    Naegeli, April
    Larkin, Amy
    Komocsar, Wendy
    Schroeder, Krista
    Zhang, Xiang
    Stefani-Hunyady, Diana
    GASTROENTEROLOGY, 2019, 156 (03) : S65 - S66